<div id="readability-page-1"><p>Avoro Capital Advisors LLC raised its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 11.0% in the fourth quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 4,355,555 shares of the company's stock after buying an additional 430,555 shares during the period. Avoro Capital Advisors LLC owned about 2.33% of Taysha Gene Therapies worth $7,709,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Taysha Gene Therapies</strong> alerts:</span></p></div><ul><li>3 Small-Cap Stocks For Your Fall Shopping List</li></ul><p>Several other institutional investors and hedge funds have also modified their holdings of TSHA. Citigroup Inc. acquired a new stake in Taysha Gene Therapies during the third quarter valued at $888,000. FMR LLC raised its holdings in shares of Taysha Gene Therapies by 2,035.0% during the 3rd quarter. FMR LLC now owns 24,527,801 shares of the company's stock valued at $77,508,000 after purchasing an additional 23,378,974 shares in the last quarter. EAM Investors LLC acquired a new position in Taysha Gene Therapies during the third quarter worth $1,060,000. Acuta Capital Partners LLC bought a new position in Taysha Gene Therapies during the third quarter valued at about $12,096,000. Finally, Vanguard Group Inc. lifted its holdings in Taysha Gene Therapies by 235.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company's stock worth $16,836,000 after purchasing an additional 3,738,616 shares during the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Taysha Gene Therapies Price Performance</h2><p>Shares of Taysha Gene Therapies stock traded down $0.03 during midday trading on Monday, reaching $3.92. The company had a trading volume of 1,005,530 shares, compared to its average volume of 2,383,907. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $733.12 million, a price-to-earnings ratio of -8.00 and a beta of 0.49. The stock has a fifty day simple moving average of $2.85 and a 200 day simple moving average of $2.28. Taysha Gene Therapies, Inc. has a 1-year low of $0.50 and a 1-year high of $4.02. </p><p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. The business had revenue of $3.41 million during the quarter, compared to analyst estimates of $3.70 million. During the same quarter last year, the business posted ($0.28) earnings per share. As a group, equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.43 earnings per share for the current year. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of research analysts recently commented on TSHA shares. Piper Sandler initiated coverage on Taysha Gene Therapies in a research note on Tuesday, April 9th. They issued an &#34;overweight&#34; rating and a $9.00 target price for the company. Needham &amp; Company LLC restated a &#34;buy&#34; rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, May 15th. Cantor Fitzgerald restated an &#34;overweight&#34; rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, May 28th. Chardan Capital raised their price target on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, March 21st. Finally, JMP Securities reiterated a &#34;market outperform&#34; rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of &#34;Buy&#34; and a consensus price target of $7.00.</p><p><b>Read Our Latest Research Report on TSHA</b></p><h2>Taysha Gene Therapies Profile</h2> (Free Report)<p>Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Taysha Gene Therapies</li><li>Investing in the High PE Growth Stocks </li><li>Our Comprehensive Risk Tolerance Assessment</li><li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li><li>Autodesk Raises Guidance After Clearing Audit Investigation </li><li>How to Read Stock Charts for Beginners</li><li>Lyft Stock Gap and Craps on Bold 2027 Guidance at Investor Day</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ It's time to ween off Chinese lithium! <span><span>(From Smallcaps Daily)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Mjgw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Mjgw"/></p><h2>Should you invest $1,000 in Taysha Gene Therapies right now?</h2><p>Before you consider Taysha Gene Therapies, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.</p><p>While Taysha Gene Therapies currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

TSHA

<p>Avoro Capital Advisors LLC has increased its stake in Taysha Gene Therapies by 11% in the fourth quarter, according to its recent filing with the Securities & Exchange Commission. Avoro Capital Advisors now owns 4,355,555 shares of the company's stock, worth $7.71 million. Other institutional investors and hedge funds have also modified their holdings of TSHA. Taysha Gene Therapies is a gene therapy company focused on developing treatments for monogenic diseases of the central nervous system.</p>

Avoro Capital Advisors LLC Has $7.71 Million Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)